Reason for request
Reassessment of medicines containing methylphenidate in attention deficit hyperactivity disorder in response to the instruction from the Directorate-General for Health.
Clinical Benefit
| Substantial |
The actual benefit of QUASYM LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years old and over when psychological, educational and social management alone prove insufficient. |
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
UkCmgeX2gq4LLYd4
